WASHINGTON - Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.

'We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation,' said Dr. Mihael H. Polymeropoulos, President, CEO and Chairman of the Board. 'We look forward to future cases that may resolve these issues for the benefit of innovators, patients and public health.'

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

Contact:

Kevin Moran

Tel: 202-734-3400

Email: pr@vandapharma.com

(C) 2024 Electronic News Publishing, source ENP Newswire